A Pilot Study of Pembrolizumab in Combination With Y90 Radioembolization in Subjects With Poor Prognosis Hepatocellular Carcinoma With Preserved Liver Function. HCRN: GI15-225
-
- STATUS
- Recruiting
Summary
The purpose of this study is to test any good and bad effects of the study drug called pembrolizumab when it is given in combination with Y90 (TheraSphere?).
Description
The purpose of this study is to evaluate the efficacy as well as the safety of combining pembrolizumab with Yttrium-90 radioembolization in subjects with poor prognosis hepatocellular carcinoma not eligible for liver transplant or surgical resection with well compensated liver function.
FAQ
Details
Condition | hepatocellular carcinoma |
---|---|
Age | 18years - 100years |
Clinical Study Identifier | TX8124 |
Last Modified on | 19 February 2024 |
Eligibility
How to participate?
Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.
Learn moreIf you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Learn moreComplete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.
Learn moreSimilar trials to consider
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteerStudy Definition
WikipediaAdd a private note
- Select a piece of text.
- Add notes visible only to you.
- Send it to people through a passcode protected link.